These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 21166611

  • 1. RETRA: evaluating the transfusion rate with darbepoetin alfa 500 µg every 3 weeks in anaemic cancer patients receiving chemotherapy.
    Eisterer W, Hussl C, Erb H, Haslbauer F, Sormann S, Braun S, Jaeger C.
    Curr Med Res Opin; 2011 Feb; 27(2):355-63. PubMed ID: 21166611
    [Abstract] [Full Text] [Related]

  • 2. Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT).
    Martelli O, Garassino M, Sacchetta S, Caristo R, Zivi A, Cerbone L, Mancuso A.
    Anticancer Res; 2008 Feb; 28(3B):1767-71. PubMed ID: 18630457
    [Abstract] [Full Text] [Related]

  • 3. A final analysis from the CHOICE study examining darbepoetin alfa use for chemotherapy-induced anaemia in current European clinical practice.
    Van Belle S, Swieboda-Sadlej A, Karanikiotis C, Labourey JL, Galid A, Wheeler T, Pujol B, Aerts JG.
    Curr Med Res Opin; 2012 Jul; 28(7):1079-87. PubMed ID: 22642867
    [Abstract] [Full Text] [Related]

  • 4. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.
    Hernandez E, Ganly P, Charu V, Dibenedetto J, Tomita D, Lillie T, Taylor K, ARANESP 20030232 Study Group.
    Curr Med Res Opin; 2009 Sep; 25(9):2109-20. PubMed ID: 19601709
    [Abstract] [Full Text] [Related]

  • 5. A prospective, observational study describing the haematological response in patients undergoing chemotherapy treated by tri-weekly darbepoetin alfa for anaemia.
    Ray-Coquard I, Laplaige P, Vey N, Asselain B, Urbieta M.
    Curr Med Res Opin; 2010 Nov; 26(11):2653-60. PubMed ID: 20932223
    [Abstract] [Full Text] [Related]

  • 6. Current practice of darbepoetin alfa in the management of haemoglobin levels in cancer patients undergoing chemotherapy - data from the CHOICE study.
    Van Belle S, Karanikiotis C, Labourey JL, Galid A, Wheeler T, Pujol B.
    Curr Med Res Opin; 2011 May; 27(5):987-94. PubMed ID: 21385113
    [Abstract] [Full Text] [Related]

  • 7. A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemia.
    Kotasek D, Canon JL, Mateos MV, Hedenus M, Rossi G, Taylor K.
    Curr Med Res Opin; 2007 Jun; 23(6):1387-401. PubMed ID: 17559735
    [Abstract] [Full Text] [Related]

  • 8. Use of darbepoetin alfa in European clinical practice for the management of chemotherapy-induced anaemia in four tumour types: final data from the CHOICE study.
    Aerts JG, Swieboda-Sadlej A, Karanikiotis C, Labourey JL, Galid A, Wheeler T, Pujol B, Van Belle S.
    Curr Med Res Opin; 2012 Jul; 28(7):1089-99. PubMed ID: 22642866
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of clinical use and effectiveness of darbepoetin alfa in cancer patients with chemotherapy-induced anemia.
    Bustos A, Álvarez R, Aramburo PM, Carabantes F, Díaz N, Florián J, Lázaro M, de Segovia JM, Gasquet JA, Alegre A, RADAR Study Group.
    Curr Med Res Opin; 2012 Jan; 28(1):57-67. PubMed ID: 22070513
    [Abstract] [Full Text] [Related]

  • 10. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy.
    Waltzman R, Croot C, Justice GR, Fesen MR, Charu V, Williams D.
    Oncologist; 2005 Sep; 10(8):642-50. PubMed ID: 16177289
    [Abstract] [Full Text] [Related]

  • 11. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial.
    20030125 Study Group TrialUniversity of California Los Angeles School of Medicine, Los Angeles, CA 90095, USA. jglaspy@mednet.ucla.edu, Glaspy J, Vadhan-Raj S, Patel R, Bosserman L, Hu E, Lloyd RE, Boccia RV, Tomita D, Rossi G.
    J Clin Oncol; 2006 May 20; 24(15):2290-7. PubMed ID: 16710026
    [Abstract] [Full Text] [Related]

  • 12. Darbepoetin alfa administered every 4 weeks for anemia in patients with advanced prostate cancer.
    Beer TM, Bergenstock M, Birt K, Higano CS.
    Clin Genitourin Cancer; 2007 Jun 20; 5(5):329-33. PubMed ID: 17645830
    [Abstract] [Full Text] [Related]

  • 13. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
    Boccia R, Malik IA, Raja V, Kahanic S, Liu R, Lillie T, Tomita D, Clowney B, Silberstein P.
    Oncologist; 2006 Apr 20; 11(4):409-17. PubMed ID: 16614237
    [Abstract] [Full Text] [Related]

  • 14. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N, Sriuranpong V.
    J Med Assoc Thai; 2005 May 20; 88(5):607-12. PubMed ID: 16149676
    [Abstract] [Full Text] [Related]

  • 15. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
    Patton J, Kuzur M, Liggett W, Miranda F, Varsos H, Porter L.
    Oncologist; 2004 May 20; 9(1):90-6. PubMed ID: 14755018
    [Abstract] [Full Text] [Related]

  • 16. The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia.
    Boccia R, Lillie T, Tomita D, Balducci L.
    Oncologist; 2007 May 20; 12(5):584-93. PubMed ID: 17522247
    [Abstract] [Full Text] [Related]

  • 17. Observational Aranesp Survey to Investigate the Q3W Schedule (OASIS): a prospective observational study of treatment of chemotherapy-induced anaemia with every 3 weeks darbepoetin alfa.
    Pat K, Anrys B, Verhulst D, Van Aelst F, Van Eygen K, Galdermans D, Verhoeven D, Polus M, Segers K, Derde MP, Wauters I, Vansteenkiste J.
    Support Care Cancer; 2009 Feb 20; 17(2):211-5. PubMed ID: 18931861
    [Abstract] [Full Text] [Related]

  • 18. Anaemia management with epoetin alfa in lung cancer patients in The Netherlands.
    Biesma B, van de Werf PR, Melissant CF, Brok RG.
    Lung Cancer; 2007 Oct 20; 58(1):104-11. PubMed ID: 17601632
    [Abstract] [Full Text] [Related]

  • 19. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia.
    Canon JL, Vansteenkiste J, Bodoky G, Mateos MV, Bastit L, Ferreira I, Rossi G, Amado RG.
    J Natl Cancer Inst; 2006 Feb 15; 98(4):273-84. PubMed ID: 16478746
    [Abstract] [Full Text] [Related]

  • 20. A prospective observational study of the effectiveness, safety, and effect on fatigue of darbepoetin alfa for the treatment of chemotherapy-induced anaemia.
    Mel JR, Salar A, Rodríguez CA, Alegre A, González A, Cassinello J, Montesinos J, Gasquet JA, Sánchez J, Saigí E, AMG-DAR-2002-01 Study Group.
    Curr Med Res Opin; 2008 Oct 15; 24(10):2931-42. PubMed ID: 18775103
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.